Inspection access is not “an administrative footnote,” leaders of key FDA divisions wrote in an editorial on Wednesday vowing to expand oversight of foreign clinical trial sites.

Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new ...

Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it ...

Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate ...

Almost as many biotechs have opted for a reverse merger to reach the public markets as those executing more traditional ...

BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of ...